The adenoma-carcinoma pathway (Fig. 1) accounts for approximately 70% of CRC and is typically associated with the early acquisition of APC mutations, which are reported in 70–80% of resulting adenocarcinomas [7, 8]. The gene discussed is APC; the disease is carcinoma.